Scrying Biotech
Long only, biotech, micro-cap, small-cap

Is Novavax On The Fast Track To Profits?

In my first article, I talked about Novavax's (NASDAQ:NVAX) revolutionary rapid formula VLP technology, a process that reduces the timeline to produce an effective vaccine by up to 83%. And in my most recent article, I addressed the proposed acquisition of adjuvant maker Isconova and expressed some reservations about the real motivations behind that move. Those apprehensions had to do with safety data from the RSV Phase 1 trial in the elderly. Novavax has responded.

A scant three days later, top-line results were revealed. And what the numbers suggest is that the acquisition of Isconova has nothing to do with tolerability data in either RSV trial. It may have to do with having tax write-offs for weekend ski...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details